[{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Milrinone","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Caplin Steriles","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caplin Steriles \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Caplin Steriles \/ Not Applicable"},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Milrinone","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Caplin Steriles","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Caplin Steriles \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Caplin Steriles \/ Not Applicable"},{"orgOrder":0,"company":"Baker Institute","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Milrinone","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Baker Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Baker Institute \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Baker Institute \/ Hyloris Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Milrinone

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Baker Institute

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Baker Institute

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the terms of the agreement, Hyloris will be responsible for the development, manufacturing, regulatory affairs, and commercialisation of CRD-102. CRD-102 is a novel, patented, extended-release Milrinone capsule.

                          Brand Name : CRD-102

                          Molecule Type : Small molecule

                          Upfront Cash : $0.1 million

                          October 08, 2021

                          Lead Product(s) : Milrinone

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Hyloris Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Caplin Steriles has been granted final approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) neostigmine methylsulfate injection USP, 5 mg/10 mL (0.5 mg/mL) and 10 mg/10 mL (1 mg/mL).

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 22, 2021

                          Lead Product(s) : Milrinone

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Caplin Steriles has been granted final approval from the USFDA for its ANDA Milrinone Lactate Injection USP, 10 mg/10 mL, 20 mg/20 mL, 50 mg/50 mL, Single-dose vial presentation, a generic therapeutic equivalent version of, PRIMACOR Injection, 1 mg/mL, o...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 19, 2021

                          Lead Product(s) : Milrinone

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank